Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Call Transcript

Dan Passeri: Yes. On 2024, obviously, we’ll have resolution from our FDA discussions, what the strategy is on 101 and also clarity on our strategic decision on what indication, what line, front line, third line, both by — in 2024, we should have also the decision of whether we’re partnering 101 and with whom, what structure? 102, as Matteo just articulated, we have a very enviable position. We have multiple cancers. We’re seeing early activity and dose escalation. Just to reiterate what Matteo conveyed during the call, we’ve seen activity at the 1 mg and 2 mg dose level. So, we also have the scans for 4 and 8 will be providing at SITC. So, going into 2024, it’s going to be a pretty exciting year just from a standpoint of prioritizing.

Obviously, in this current financial climate, we have resource requirements that we’re going to have to address. So most likely through strategic. We also have data from 401 that is emerging, we’ll have clarity by end of year going into 2024. We consider that to be a really important transitional year for us. So, I think it’s going to be a year of multiple milestones that will be clearly defining by the end of the year as well as expansion decisions.

Unidentified Analyst: Thank you.

Dan Passeri: Okay. Yes, appreciate it.

Operator: Thank you. At this time, there are no further questions. Please proceed with your closing remarks.

Dan Passeri: Yes. I want to thank everyone for your time and interest in our continued progress. We’re clearly making very good steady progress as we move forward, and we’re looking forward to SITC and providing you with further updates as we continue developing for the remainder of the year. I wish everyone a pleasant remainder of the week. And again, thank you for your interest and take care.

Operator: This concludes your conference call for today. You may now disconnect your lines. Thank you.